Effects of Reduced Nicotine Content Cigarettes on Fractional Exhaled Nitric Oxide and Self-Reported Respiratory Health Outcomes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage.

Plain-language guide to PMID 34255068 (2022): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 34255068
Journal: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Year: 2022
Study type: Randomized Controlled Trial
Authors: Oliver AC et al. (14 authors)
DOI: 10.1093/ntr/ntab145
Registered trial: NCT02250664, NCT02232737, NCT02250534

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

FeNO levels and RHQ ratings were collected at baseline and Weeks 6 and 12 following randomization.

Multiple regression was used to assess associations of FeNO and RHQ with smoking characteristics.

Mixed-model repeated-measures ANOVA was used to evaluate the effects of nicotine content on FeNO and RHQ outcomes over the 12-week study period.

Why It Was Studied

Inclusion and exclusion criteria for the sample and experimental manipulation of the nicotine content of assigned cigarettes are registered: NCT02232737, NCT02250664, NCT02250534.

The FeNO measure reported in this manuscript is an exploratory outcome that was not registered.

Who Took Part

PubMed indexes the participants as adults.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

The FeNO measure reported in this manuscript is an exploratory outcome that was not registered.

The subject headings attached to it are Fractional Exhaled Nitric Oxide Testing, Nicotine, Outcome Assessment, Health Care, Respiratory System, Self Report, Smokers and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.